INT217723

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 2003
Last Reported 2009
Negated 3
Speculated 1
Reported most in Body
Documents 15
Total Number 16
Disease Relevance 2.12
Pain Relevance 0.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lysosome (IDS)
Anatomy Link Frequency
muscle 5
chest 1
IDS (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 129 96.52 Very High Very High Very High
imagery 69 95.84 Very High Very High Very High
adenocard 9 90.80 High High
Central nervous system 12 72.80 Quite High
lidocaine 6 71.32 Quite High
anesthesia 10 70.88 Quite High
Inflammation 16 5.00 Very Low Very Low Very Low
tolerance 9 5.00 Very Low Very Low Very Low
Pain 8 5.00 Very Low Very Low Very Low
agonist 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Coronary Artery Disease 135 98.40 Very High Very High Very High
Aging 57 98.20 Very High Very High Very High
Mucopolysaccharidoses 7 97.92 Very High Very High Very High
Fabry Disease 1 96.84 Very High Very High Very High
Angina 84 96.52 Very High Very High Very High
Gauchers Disease 2 96.24 Very High Very High Very High
Cardiovascular Disease 27 94.44 High High
Injury 12 93.72 High High
Obesity 12 91.44 High High
Stress 106 91.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Another factor influencing use of MPS is the quality of studies.
Regulation (influencing) of MPS
1) Confidence 0.25 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 0.09 Pain Relevance 0.05
No targets were proposed for MPS except indirectly by requiring completion of diagnosis and assessment in rapid access chest pain clinics within 2 weeks.
Neg (No) Regulation (targets) of MPS in chest associated with angina
2) Confidence 0.15 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 0.25 Pain Relevance 0.10
In general terms, however, the sensitivity of exercise MPS for detecting angiographically defined CHD is consistently above 70%, but in the better designed studies it is in the region of 85–90% [13, 14, 15].
Regulation (sensitivity) of MPS associated with coronary artery disease
3) Confidence 0.15 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 0.39 Pain Relevance 0.11
Recombinant iduronate-2-sulfatase (idursulfase, Elaprase®; Shire HGT Pharmaceuticals, Cambridge, MA, USA) was approved in July, 2006 in the US and January, 2007 in Europe as a safe and effective treatment for individuals with MPS II.
Regulation (effective) of idursulfase
4) Confidence 0.09 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.49 Pain Relevance 0.09
To our knowledge the current work is the first to demonstrate in human beings sex differences in the rate of MPS and provides some insight concerning the control of MPS and the different rates of muscle loss with aging between men and women.
Regulation (control) of MPS in muscle associated with aging
5) Confidence 0.06 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267222 Disease Relevance 0.28 Pain Relevance 0
Oddly, however, the effect of testosterone therapy in older men is unclear; it has been shown by the same group, in different studies, to either increase [42] or not to affect [43] the basal rate of MPS.
Neg (not) Regulation (affect) of MPS
6) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267222 Disease Relevance 0.23 Pain Relevance 0
Furthermore, the expression in muscle of mRNA for myostatin and myoD, cell regulatory proteins affecting muscle size [26]–[29], was not different between the sexes, which makes it unlikely that they are involved in regulating the basal rate of MPS, although, we cannot from our data rule out differences in the muscle myostatin and myoD protein concentration (and thus in cell function).
Regulation (regulating) of MPS in muscle
7) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267222 Disease Relevance 0.06 Pain Relevance 0
At 210 min after the start of the leucine tracer infusion, a second muscle biopsy was obtained to determine the basal rate of MPS (as incorporation of [5,5,5-2H3]leucine into muscle protein; see Calculations) and the basal concentrations of phosphorylated elements of intramuscular signal transduction proteins (Akt; p70s6k; eIF-4E; eIF4E-BP1; and eEF2) involved in the regulation of MPS.
Regulation (regulation) of MPS in muscle
8) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267222 Disease Relevance 0 Pain Relevance 0.14
To date, there is no evidence that the sensitivity of MPS in older men and women to insulin released by feeding is different.
Regulation (sensitivity) of MPS
9) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267222 Disease Relevance 0.08 Pain Relevance 0
In summary, we have demonstrated that there is significant sexual dimorphism in MPS and its control in older adults; a greater basal rate of MPS, operating over a large portion of the diurnal cycle, may be, at least in part, responsible for the slower loss of muscle in women than in men.



Regulation (control) of MPS in muscle
10) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267222 Disease Relevance 0.08 Pain Relevance 0
This, too, had power to influence MPs.
Regulation (influence) of MPs
11) Confidence 0.01 Published 2009 Journal Medical History Section Body Doc Link PMC2629176 Disease Relevance 0.08 Pain Relevance 0
The results of testing these hypotheses should provide valuable insights into the importance of these molecules for the regulation of MPS and MPB measured concurrently.
Regulation (regulation) of MPS
12) Confidence 0.01 Published 2008 Journal American Journal of Physiology - Endocrinology and Metabolism Section Body Doc Link PMC2536736 Disease Relevance 0.09 Pain Relevance 0
In response to increased availability of amino acids and insulin, there appear to be changes in the phosphorylation of anabolic signaling molecules and amounts of enzymes associated with the ubiquitin-proteasome pathway that cannot be easily reconciled with alterations in MPS, LPS, and LPB and that change our view of the nature of regulation of muscle protein balance by amino acids and insulin.
Regulation (alterations) of MPS in muscle
13) Confidence 0.01 Published 2008 Journal American Journal of Physiology - Endocrinology and Metabolism Section Body Doc Link PMC2536736 Disease Relevance 0 Pain Relevance 0
Some of the present results were predictable from what had previously been reported [e.g., the effects of amino acids on MPS (1–3, 8), insulin plus amino acids and the effects of insulin on LPB (14, 22)].
Regulation (effects) of MPS
14) Confidence 0.01 Published 2008 Journal American Journal of Physiology - Endocrinology and Metabolism Section Body Doc Link PMC2536736 Disease Relevance 0 Pain Relevance 0
However, it was surprising that adding insulin at higher than systemic postabsorptive concentrations had no further effects on MPS or LPS.
Neg (no) Regulation (effects) of MPS
15) Confidence 0.01 Published 2008 Journal American Journal of Physiology - Endocrinology and Metabolism Section Body Doc Link PMC2536736 Disease Relevance 0 Pain Relevance 0
First, Dangin et al. [26] investigated the effect of digestion rates on WBPS, while Padon-Jones et al. [64] investigated the effects of a meal and supplement on MPS.
Spec (investigated) Regulation (effects) of MPS
16) Confidence 0.00 Published 2006 Journal J Int Soc Sports Nutr Section Body Doc Link PMC2129150 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox